Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imilecleucel-T

- PMLiVE

Merck Serono appoints chief medical officer

Steven Hildemann joins from Merck & Co

- PMLiVE

Royalty Pharma buys bigger Tecfidera interest

Agrees $510m deal with Biogen Idec for IP share of multiple sclerosis drug

- PMLiVE

Genzyme shocked by FDA’s rejection of Lemtrada

US regulator refuses to approve MS drug on safety grounds

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

Kleemann joins Merck from Boehringer

Appointed head of group tax

- PMLiVE

Two firms join Merck Serono’s Israeli bioincubator

Metabomed to focus on cancer while ChanBio is developing treatments for MS

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

Sales down at Merck Serono on Rebif pressure

New MS drugs impact pharma company’s revenues

Biogen Idec building

Rocketing Tecfidera sales give Biogen Idec stellar Q3 results

Oral MS drug on course for blockbuster status in first year

- PMLiVE

Merck pushes for fertility discussion

Pharma company-sponsored research shows couples are leaving it too late to discuss having children

- PMLiVE

Merck Serono completes move to Germany

Closes Swiss headquarters to take up residence with parent company in Darmstadt

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links